The effect of geographic location on Circannual Adrenocorticotropic hormone plasma concentrations in horses in australia by Secombe, C.J. et al.
The Effect of Geographic Location on Circannual
Adrenocorticotropic Hormone Plasma Concentrations in
Horses in Australia
C.J. Secombe , R.H.H. Tan, D.I. Perara, D.P. Byrne, S.P. Watts, and J.G. Wearn
Background: Longitudinal evaluation of plasma endogenous ACTH concentration in clinically normal horses has not
been investigated in the Southern Hemisphere.
Objectives: To longitudinally determine monthly upper reference limits for plasma ACTH in 2 disparate Australian geo-
graphic locations and to examine whether location affected the circannual rhythm of endogenous ACTH in the 2 groups of
horses over a 12-month period.
Animals: Clinically normal horses <20 years of age from 4 properties (institutional herd and client owned animals) in
Perth (n = 40) and Townsville (n = 41) were included in the study.
Methods: A prospective longitudinal descriptive study to determine the upper reference limit and confidence intervals for
plasma ACTH in each geographic location using the ASVCP reference interval (RI) guidelines, for individual months and
monthly groupings for 12 consecutive months.
Results: Plasma endogenous ACTH concentrations demonstrated a circannual rhythm. The increase in endogenous
ACTH was not confined to the autumnal months but was associated with changes in photoperiod. During the quiescent per-
iod, plasma ACTH concentrations were lower, ≤43 pg/mL (upper limit of the 90% confidence interval (CI)) in horses from
Perth and ≤67 pg/mL (upper limit of the 90% CI) in horses from Townsville, than at the acrophase, ≤94 pg/mL (upper limit
of the 90% CI) in horses from Perth, ≤101 pg/mL (upper limit of the 90% CI) in horses from Townsville.
Conclusions and Clinical Importance: Circannual rhythms of endogenous ACTH concentrations vary between geographic
locations, this could be due to changes in photoperiod or other unknown factors, and upper reference limits should be deter-
mined for specific locations.
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Measurement of endogenous ACTH in plasma isthe most frequently used screening test to diag-
nose the common equine endocrinopathy pituitary pars
intermedia dysfunction (PPID).1,2 Seasonal variation of
plasma concentration of this hormone in clinically nor-
mal horses and horses with PPID is well recognized,
with higher autumnal plasma ACTH concentrations in
both the Northern and Southern Hemispheres.3–5 The
variation in plasma ACTH concentration in healthy horses could be reflective of a circannual rhythm related
to changing photoperiod.6
Upper reference limits of plasma ACTH concentration
have been determined by examination of individual
horses, with plasma ACTH measured at a single time
point.3,5 There are a number of studies that have longitu-
dinally evaluated clinically normal horses over a 12-
month period; however, these studies have not had suffi-
cient sample size to generate an upper reference limit.4,7–9
The first objective of the study was to longitudinally
determine monthly upper reference limits for plasma con-
centration of ACTH in 2 disparate locations within Aus-
tralia. The second objective was to examine whether
geographic location within Australia affected the circan-
nual rhythm of plasma concentration of ACTH in the 2
groups of clinically normal horses over a 12-month period.
Materials and Methods
The upper reference limit for plasma ACTH was determined
using the American Society of Veterinary Clinical Pathology
(ASVCP) RI guidelines.10
Study Population
Horses were selected at each of 2 geographic locations within
Australia; Perth in southern Australia (31°570S, 115°520E) and
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Townsville in northern Australia (19°260S, 146°81E). The study
population was recruited from 4 properties at each location. A
thorough clinical examination was performed on all candidates,
and horses were only included if they did not have any clinical
signs consistent with PPID and were less than 20 years of age.
Ethics approval was obtained from Murdoch University Animal
Ethics Committee (Approval number R2702/14) and James Cook
University Animal Ethics Committee (Approval number A2127).
Sample Collection
Sample collection began in March 2015 and ended in February
2016. Before each sample collection, all horses had physical exami-
nations, including body condition scoring,11 palpation of fore feet
digital pulses, walking and turning in a tight circle in both direc-
tions. Any horse that had an increased digital pulse or was hesi-
tant on turning had a hoof tester examination. Horses were
sampled in their own environment, either in their paddocks or
when they came into the yard for routine activities. Horses were
all sampled in the morning (within 2 hours of each individual
horse’s previous sample collection) in the middle of each month.
Blood was collected from the left jugular vein through a 20-g 1.5-
inch vacutainer needle into evacuated 4-mL plastic tubes contain-
ing EDTAa and evacuated 4-mL plastic plain tubes.b The samples
collected into tubes containing EDTA were placed on ice within
1 minute of collection and were centrifuged within 4 hours in a
refrigerated centrifuge at 4000 9 g for 5 minutes. Plasma and
serum were aliquoted and placed into plastic vialsc and stored in a
80°C freezer until batch sample processing 1–12 months later.
Data on day length at each location were gathered from Geo-
science Australia.d A subset of horses in each location had a TRH
stimulation test as previously described, to further support case
selection based on clinical normality.12
ACTH Analysis and Quality Control
Frozen plasma samples were transported on dry ice, and plasma
ACTH concentrations analyzed using an Immulite 1000 ACTH
solid-phase, 2-site sequential, chemiluminescent immunometric
assaye performed on an Immulite 1000 analyzerf at IDEXX
laboratories.g The analytical sensitivity of the assay is 9 pg/mL.e
Quality control materials provided by the manufacturer were used
daily (Immulite ACTH control module). The coefficients of varia-
tion for lower (29 pg/mL) and upper (414 pg/mL) level quality
control materials were 4.16% and 5.07%, respectively, and were
deemed acceptable.h
Statistical Analysis
Monthly data were tested for normality using the Shapiro-Wilk
test and log-transformed if normality was not met. Outliers were
identified by both the Tukey and the Reed method and were
removed if determined to be aberrant observations. An aberrant
observation was defined as a plasma ACTH value that was not
comparable to the months preceding and after in that individual
horse when all other monthly values for that horse were compara-
ble to the rest of the group. Reference intervals and confidence
intervals (CI) for plasma ACTH were calculated using parametric
methodology by the software package R-studioi and robust
methodology by MedCalc 16.4.3 software.j Statistical significance
was assumed when P ≤ 0.05.
Repeated measures ANOVA with Bonferroni’s correction was
used to determine differences in plasma ACTH over each individ-
ual month. When monthly means were not statistically different
from each other, they were grouped and linear mixed modeling
was used to determine the means and standard deviations to be
representative of each group. Reference intervals were determined
using the mean  2 standard deviations as the upper and lower
reference limits, respectively, and 90% CI were obtained for the
upper and lower reference limits.
Results
The final study cohort in Perth included 40 horses;
the age range of horses was 4–15 years with an average
and median age of these horses being 10.3 and 10.5 years,
respectively. For 31 horses, samples were available for
12 months, with 9 horses having samples available over
11 months. Horse breeds were mixed and included Thor-
oughbreds (n = 11), Standardbreds (n = 12), Warm-
bloods (n = 3), mixed breeds (n = 6), and ponies (n = 8);
there were 26 geldings and 14 mares. Thirty-eight horses
were kept in paddocks and received supplemental feed of
either roughage only or grain and roughage depending
on their level of physical activity. Two horses were
stabled at night and paddocked during the day for the
majority of the study. All horses received routine anthel-
mintic care; vaccination status was unknown.
The final study cohort in Townsville included 41
horses, with an age range of 3–19 years; the average
and median age of these horses was 11.6 years and
12 years, respectively. For 35 horses, samples were
available for 12 months, with 6 horses having samples
available over 11 months. There were 37 mares, 3 geld-
ings, and 1 stallion. Breeds represented were Thorough-
breds (n = 23), Standardbreds (n = 7), Quarter Horses
(n = 4), Australian Stock Horses (n = 6), and Warm-
blood horses (n = 1). All horses in the Townsville
cohort were paddock housed and received supplemental
feed of roughage only or grain and roughage depending
on their level of physical activity. All horses received
routine anthelmintic care and were vaccinated against
tetanus and Hendra virus.
For the duration of the study, on intermittent occa-
sions, individual horses in both cohorts had transient
variations in foot related physical examination vari-
ables; however, no horse developed laminitis or other
clinical signs consistent with PPID. For those individual
horses that undertook some form of exercise in the pre-
ceding 24 hours, it was not deemed to be excessive. No
horse was determined to be unwell on the day of sample
collection.
Perth Data
Normality was not met, and monthly data were log-
transformed to meet a Gaussian distribution. This was
achieved for all months except July. Three outliers from
different horses were removed from the data set; 2 from
April (120 pg/mL and 138 pg/mL) and 1 from Septem-
ber (79.7 pg/mL). The outliers were considered to be
unusual values as plasma ACTH in the months preced-
ing and after were comparable to the rest of the group.
The range and median plasma ACTH values (pg/mL)
of each of these horses after outlier removal were 23.0–
63.5 (31.8), 15.4–63.4 (28.4), and 23.3–62 (35.1), respec-
tively. Additionally, 2 of the 3 horses with outlier values
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had a TRH stimulation test performed and the plasma
ACTH did not exceed concentrations after stimulation
recommended by the equine endocrinology group.13
Laboratory error in December resulted in 6 samples
being excluded that month and 3 horses were unavail-
able for collection in January. Sample sizes for each
month were 40 with the exception of September
(n = 39), December (n = 34), January (n = 37), and
April (n = 38). Summary of data is presented in Table 1
(median, maximum, and minimum values). Upper refer-
ence limits and 90% CI are presented in Table 2. Confi-
dence interval width compared to reference limit width
ranged from 0.33 to 0.49.
The repeated measures ANOVA with Bonferroni’s
correction suggested groupings of: June to November;
December, January, and May; and February to April.
Each of these groups was then analyzed using linear
mixed modeling which more accurately accounts for
between and within subject (horse) variation, to deter-
mine mean plasma ACTH concentrations to represent
the groups and months within each group. For the first
group, when June was compared with July (P = 0.186),
August (P = 0.468), September (P = 0.576), October
(P = 0.312), and November (P = 0.065), there was no
significant difference in mean plasma ACTH concentra-
tions. For the second grouping, when the month of Jan-
uary was compared to May there was no significant
difference (P = 0.552); when compared to December
(P = 0.043), the means were significantly different. For
the third grouping, when the month of April was com-
pared to March there was no significant difference
(P = 0.172); when compared to February (P = 0.014),
the means were significantly different. Although groups
2 and 3 did not achieve complete statistical homogene-
ity when analyzed using linear mixed modeling, they
did so using repeated measures ANOVA and from a
biological perspective these groupings were deemed
valid. The upper reference limits and 90% CI were
determined for each grouping (Table 3). Confidence
interval width compared to reference limit width in the
grouped data ranged from 0.14 to 0.22.
Townsville Data
Normality was not met, and monthly data were log-
transformed to meet a Gaussian distribution. This was
achieved for all months except August, September, and
December. Six outliers from different horses were
removed from the data set; 1 each from November
(185.0 pg/mL), December (104.0 pg/mL), and January
(101.0 pg/mL), and 3 from February (101.0 pg/mL,
113.0 pg/mL, 200.0 pg/mL). The outliers were consid-
ered to be unusual values as plasma ACTH in the
months preceding and after were comparable to the rest
of the group. The range and median plasma ACTH val-
ues (pg/mL) of each of these horses after outlier
removal were as follows: 41.90–88.10 (60.8), 31.20–
60.80 (39.3), 25.4–63.9 (36.5), 23.6–87.5 (41.6) 29.5–89.9
(48.8), 14.4–43.4 (27.7), respectively. Additionally, 3 of
the 6 horses with outlier values had a TRH stimulation
test performed and the plasma ACTH did not exceed
concentrations after stimulation recommended by the
equine endocrinology group.13 Laboratory error or
horses being unavailable for collection resulted in 2
samples being excluded for the month of January, and
1 sample being excluded from August, September, Octo-
ber, and February. Sample size was 41 for March-July,
40 for August-December, 38 for January, and 37 for
Table 1. Plasma ACTH concentrations from the raw
data used to generate reference intervals before log
transformation from the Perth cohort.
Month Median ACTH concentration (pg/mL) (range), n
July 21.40 (15.30–44.50), 40
August 23.40 (10.30–41.40), 40
September 21.60 (12.40–33.70), 39
October 24.20 (13.80–38.70), 40
November 25.40 (16.00–44.30), 40
December 27.80 (16.50–53.30), 34
January 28.40 (19.20–59.60), 37
February 36.10 (19.60–70.30), 40
March 44.65 (23.00–80.50), 40
April 40.55 (28.50–67.60), 38
May 29.80 (16.30–68.00), 40
June 23.30 (14.80–49.50), 40
Table 2. Plasma ACTH upper reference values (90%
CI) using parametric and robust methodology for the
samples from horses in Perth.
Plasma ACTH (pg/mL)
Month Parametric (90% CI) Robust (90%CI)
July * 34.37 (30.20–39.91)
August 42.30 (32.23–48.06) 41.89 (35.59–49.71)
September 35.65 (32.15–39.53) 36.37 (31.68–40.15)
October 37.72 (34.17–41.65) 38.56 (34.78–42.32)
November 41.68 (37.21–46.69) 41.46 (37.06–46.72)
December 48.48 (42.62–55.14) 46.72 (42.41–56.33)
January 53.86 (47.12–61.56) 56.33 (45.95–62.25)
February 68.70 (59.83–78.89) 69.93 (60.36–79.48)
March 81.97 (71.60–93.86) 83.20 (71.12–94.47)
April 65.38 (58.93–72.53) 64.82 (57.06–73.13)
May 54.70 (48.13–62.17) 53.89 (45.74–62.78)
June 40.21 (35.49–45.35) 40.38 (35.79–45.33)
*Data not normally distributed after log transformation there-
fore parametric analysis not applicable.
CI, Confidence interval.
Table 3. Plasma ACTH upper reference values with
90% CI using grouped data from horses sampled in
Perth.
Month
Upper reference values
(pg/mL) (90% CI)
June–November 41.12 (39.3–43.01)
May/December/January 52.51 (48.77–56.54)
February–April 78.18 (72.72–84.04)
CI, Confidence interval.
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February. Summary of data is presented in Table 4
(median, maximum, and minimum values). Upper refer-
ence limit and 90% CI are presented in Table 5.
Confidence interval width compared to reference limit
width ranged from 0.34 to 0.45.
The repeated measures ANOVA with Bonferroni’s
correction suggested grouping as follows: April to
September and December; June, October, and Novem-
ber; January and February; with March as a stand-
alone month. Each of these groups was then analyzed
using linear mixed modeling as for the Perth data. For
the first group, when the month of August was com-
pared with July (P = 0.105), September (P = 0.637),
December (P = 0.068), April (P = 0.129), and May
(P = 0.308), there was no significant difference in mean
plasma ACTH concentrations. However, the month of
June was significantly different (P = 0.033). For the sec-
ond grouping suggested by the repeated measures
ANOVA, June was significantly different in mean
plasma ACTH concentrations to October (P = 0.0002)
and November (P = 0.02). October was significantly dif-
ferent to November (P = 0.03). Hence, these months
were treated as stand-alone months in the analysis. For
the third grouping, February was significantly different
to January (P = 0.009). As a result, January, February,
and March are all treated as stand-alone months
(Table 6). Confidence interval width compared to refer-
ence value width in the grouped data inclusive of the
individual months ranged from 0.16 to 0.45.
Day Length
The shortest day of the year (winter solstice) occurred
on June 22, 2015 and the longest day of the year (sum-
mer solstice) on December 22, 2015. The equinox dates
for 2015 were March 21 and September 23. Day length
changes in comparison with plasma ACTH concentra-
tions at each location are presented in Figure 1.
Discussion
This study generated individual normal upper refer-
ence limits for plasma ACTH concentration for each
month of the year and specific monthly groupings in 2
geographic locations within the Southern Hemisphere.
This study differs from previous studies in that sufficient
individual clinically normal horses were longitudinal
tracked monthly over a 12-month period to generate
monthly upper reference limits and confidence intervals.
Endogenous ACTH in this study had a circannual
rhythm, consistent with other studies.3–5,7–9,14–16 The
increase in plasma ACTH was not confined to only the
autumnal months as has been previously described3–5,8,9
but was consistent with the change in photoperiod as
has been described by Durham.6
The generation of veterinary reference limits should
follow specific guidelines, and within this study, the
ASVCP guidelines10 were used. Although it was the
intention to utilize a sample size of 40 horses for each
month, this was not possible. As all sample sizes were
greater than 20 and as plasma ACTH concentrations of
most months were considered Gaussian in their distri-
bution after transformation, both robust and parametric
methodologies were performed to determine the
Table 4. Plasma ACTH concentrations from the raw
data used to generate reference intervals before log
transformation from the Townsville cohort.
Month Median ACTH concentration (pg/mL) (range), n
July 30.60 (19.00–59.50), 41
August 33.25 (12.10–88.10), 40
September 30.30 (20.60–79.10), 40
October 23.35 (10.70–61.40), 40
November 24.00 (10.50–89.90), 40
December 29.95 (19.30–82.90), 40
January 34.95 (21.00–78.00), 38
February 40.90 (27.20–75.90), 37
March 48.60 (31.00–99.80), 41
April 34.70 (18.10–66.30), 41
May 34.30 (18.90–79.90), 41
June 29.70 (17.80–60.80), 41
Table 5. Plasma ACTH upper reference values (90%
CI) using parametric and robust methodology for the
samples from horses in Townsville.
Plasma ACTH (pg/mL)
Month Parametric (90% CI) Robust (90%CI)
July * 50.76 (45.07–56.60)
August 62.66 (54.16–72.48) 62.25 (50.74–75.61)
September * 60.34 (49.41–70.80)
October 45.42 (39.19–52.64) 44.40 (37.00–52.85)
November 55.38 (46.38–66.14) 56.48 (45.12–68.42)
December * 45.69 (37.95–55.25)
January 76.55 (65.56–89.4) 77.21 (62.02–91.64)
February 75.59 (66.74–85.63) 76.35 (64.88–87.14)
March 88.90 (78.48–100.71) 88.87 (77.49–101.34)
April 73.09 (62.09–86.05) 73.38 (60.24–86.09)
May 68.58 (58.75–80.05) 67.18 (56.26–80.11)
June 49.94 (44.33–56.26) 49.45 (43.46–56.26)
*Data not normally distributed after log transformation there-
fore parametric analysis not applicable.
CI, Confidence interval.
Table 6. Plasma ACTH upper reference values with
90% CI using grouped data from horses sampled in
Townsville.
Month
Upper reference values
(pg/mL) (90% CI)
July–September, December, April–May 62.92 (59.55–66.49)
October 45.42 (39.19–52.64)
November 55.38 (46.38–66.14)
January 76.55 (65.56–89.40)
February 75.59 (66.74–85.63)
March 88.90 (78.48–100.71)
June 49.94 (44.33–56.26)
CI, Confidence interval.
1536 Secombe et al
reference limits and median, maximum, and minimum
plasma ACTH values are presented (Tables 1 and 4).
Two methodologies were employed as similarity in RI,
as was demonstrated in this case, supports a homoge-
nous population.17
Reference intervals are essential to assist a clinician
in making a clinical decision regarding the presence or
absence of disease. Reference limits only describe the
variability of the measured analyte within a population
of normal animals and the value at which the analyte
should be considered normal in the general population
is not below the upper reference limit, but can be con-
sidered to be below the upper limit of the CI.18 Confi-
dence intervals were calculated for all months by both
the parametric and robust methodologies and were
found to be similar (Tables 2 and 5). The CI widths
compared to the width of the RI for all months in both
data sets exceeded 0.2; the recommendation suggested
by the ASVCP.10 This is not surprising given these cri-
teria cannot be met with a sample size of less than 55.18
When monthly data were grouped, the CI widths com-
pared to the width of the RI were ≤ 0.2. When assessing
analytes where there is a pronounced difference between
health and disease, as has been shown in particular with
autumnal plasma ACTH concentrations in horses with
clinical signs of PPID,3,5,8 higher imprecision around
the upper reference limit should not affect clinical
interpretation.18
Two distinct periods were identified within the circan-
nual rhythm of endogenous ACTH. A period when the
upper reference limit for plasma ACTH was lower com-
pared to the rest of the year with little variability and is
defined by the authors as the “quiescent phase.” This
was June to November (6 months) inclusive in Perth as
these months were statistically homogenous. In Towns-
ville, the quiescent period might be from April to
December (9 months) as suggested by statistical analy-
sis; however, it is possible it follows a similar pattern
to Perth (Fig 1), which only might become evident
with larger sample sizes or investigation with other
endocrine tests such as monthly TRH stimulation test-
ing. A second period commences when plasma ACTH
begins to increase, reaches a peak (acrophase), and
then declines, this period has been defined by the
authors as the “dynamic phase.” The upper reference
limits during this phase were higher and more variable.
Geographic location appeared to influence the length
of the dynamic ACTH phase with a potentially longer
dynamic phase the further south the location. In both
locations, the plasma ACTH upper reference limit was
similar at the acrophase (March in both locations) and
coincided with the autumn equinox. The authors sur-
mised the greater the change in circannual photoperiod
the lower the upper reference limit of plasma ACTH
during the quiescent phase with a potentially longer
dynamic phase of ACTH. This is supported by the
upper reference limit of plasma ACTH in Perth being
lower than in Townsville during the quiescent period.
If one of the roles of ACTH is to alter equine metabo-
lism in preparation for winter, it seems reasonable to
assume that less circannual fluctuation would occur in
tropical equatorial regions that have an absence of
true “seasons.” Further research would need to be
undertaken to determine whether in addition to pho-
toperiod factors such as climate have a role in circan-
nual rhythm of ACTH.
Due to the monthly variation during the dynamic
phase, grouping of the data was problematic. In Perth,
2 of the groupings chosen, February to April inclusive
and December, January, and May did not display com-
plete statistical homogeneity within the groups; how-
ever, these 2 groupings were maintained from a clinical
Fig 1. Circannual plasma ACTH upper reference values (Townsville , Perth ) and day length change (Townsville , Perth ).
Parametric with robust values for months with non-normal data distribution. [Color figure can be viewed at wileyonlinelibrary.com]
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decision-making perspective as there was little difference
in the upper reference limits suggesting biological simi-
larity. It is up to the individual clinician to determine
whether they wish to use a monthly CI upper limit or a
grouped CI upper limit. In Townsville, plasma ACTH
concentrations during the dynamic phase did not dis-
play any statistical homogeneity and as such clinicians
are recommended to use monthly CI upper limits for
that period. Plasma ACTH concentrations were lower
in June, October, and November within the proposed
quiescent period of April to December; the clinical rele-
vance of this is unknown; hence, individual clinicians
should determine whether they wish to use the higher
CI upper limit for the grouped months (July, August,
September, December, April, and May) from April to
December inclusive or use monthly CI upper limits.
Although a cutoff value of plasma ACTH in clinically
normal horses for a latitude between the 2 locations of
this study has been reported,5 samples were collected
from horses at a single time point, data were grouped
into seasons, and a differing statistical methodology was
used; therefore, it is difficult to compare the 2 studies.
Within that study,5 the cutoff value for both the autum-
nal and nonautumnal periods was lower than either the
Perth or Townsville limit of the upper CI. The authors
are of the opinion that this is not due to case selection
criteria as this study used younger animals with no clin-
ical signs of PPID where disease prevalence is lower,
rather it is likely to be due to that study’s use of an
alternate statistical methodology.
Although the limit of the upper CI for plasma ACTH
during the dynamic phase in both Australian locations
was similar to what has been reported in the Northern
Hemisphere,13 the limit of the upper CI for the quies-
cent phase was higher compared to the Northern Hemi-
sphere. This might be due to study design or the
probability that local geographic and management fac-
tors have a combined effect with photoperiod in deter-
mining regulation of ACTH secretion. It must be
acknowledged that if plasma ACTH concentrations
exceed the limit of the upper CI, this does not necessar-
ily confirm that the horse has PPID. Clinical decision
limits, that is the value at which it is likely the animal
has the disease, differ from reference limits and are usu-
ally based on guidelines reached from a group consen-
sus of expert individuals.19 With regard to PPID,
guidelines regarding clinical decision limits continue to
be reviewed, particularly in the Southern Hemisphere,
as further research is conducted.
The selection criteria used to choose horses were
similar to previous studies with both age and the
absence of clinical signs associated with PPID guiding
the inclusion of horses.3,5,20 The inadvertent inclusion
of horses with subclinical PPID was thought to be
unlikely in this study as a subset of horses had TRH
stimulation tests during the quiescent ACTH phase
and were determined to be normal (unpublished data).
In addition, prevalence of the disease is low in younger
horses21,22 and horses were sampled on multiple occa-
sions so that if persistently increased levels were
detected suggestive of PPID they could be excluded.
Age does not affect plasma ACTH concentration in
healthy horses23 and as such the benefits of using a
younger population with a lower prevalence of disease
were thought to outweigh the risk of inadvertent inclu-
sion of horses with subclinical disease had an older
population been used.
Similar to other studies determining the upper limit
of plasma ACTH3,5 or the effect of location,20 sex was
not standardized across locations as sex does not affect
plasma ACTH in equids.14 Horses were only sampled at
one time point on collection days as paired or multiple
samples have not been shown to confer a benefit over a
single measurement.24,25 Although the literature is con-
flicting as to whether endogenous ACTH in horses has
a well-defined circadian rhythm, all samples were col-
lected within the same 2 hour time period each month
to ensure consistency.15,16,25
On several occasions, isolated unusual plasma ACTH
increases were detected that exceeded the upper refer-
ence limit for that time of year, predominantly during
the ACTH dynamic phase when increased variability
was appreciated. Within this study, an explanation as to
why the isolated unusual increases occurred could not
be provided as the horses were in good health and had
not been subjected to perceivable physiological stress,
which has been implicated in increasing plasma ACTH
concentrations in horses.26,27 These findings support the
notion that if a single plasma ACTH test is being used
to screen for PPID, interpretation should be taken in
light of clinical presentation and repeat testing or per-
forming a TRH stimulation test might be preferable
over initiation of treatment.
Limitations of this study are that horses were only
evaluated longitudinally for 12 months and the
assumption is made that the 12-month period chosen
is representative of the circannual rhythm; however, it
is unknown whether this is the case. Secondly as this
was not a terminal study, it is unknown whether these
horses had subclinical PPID; however, this limitation
is shared with many other studies evaluating plasma
ACTH in clinically normal horses. Finally, ideally the
horses would have been breed matched across each
location with only 1 breed utilized as although previ-
ous work has suggested that there is no difference in
plasma ACTH between ponies and horses,5,14,20 emerg-
ing literature28 suggests ACTH might differ between
breeds.
In conclusion, this study achieved the aims of deter-
mining monthly RIs for 2 disparate locations within
Australia. We demonstrated that the circannual
rhythm is characterized by a quiescent phase where the
upper reference limit of plasma ACTH is lower and
variable between locations, but higher than those cur-
rently reported for the Northern Hemisphere. In com-
parison, there is a dynamic ACTH phase which results
in a similar acrophase at the autumn equinox in both
locations and the Northern Hemisphere. In Australia
at locations closer to the equator, horses might have a
shorter dynamic phase to their circannual ACTH
rhythm with higher reference limits during the quies-
cent phase.
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Footnotes
a Greiner Bio-One 4 mL plastic whole blood tube with spray
coated K2EDTA, reference number 454023, Germany
b Greiner Bio-One 4 mL plastic whole blood tube with serum clot
activator, reference number 454204, Germany
c Cryo.S cryovials, Greiner Bio-One GmbH, Germany
d Geo Science Australia http://www.ga.gov.au/
e Siemens Immulite/Immulite 1000ACTH assay, Australia
f Siemens Immulite/Immulite ACTH control module, Australia
g IDEXX Laboratories Pty Ltd, Unit 6, 38 – 46 South St, Rydal-
mere NSW 2116 Australia
h The Royal College of Pathologists of Australasia and the
Australasian Clinical Biochemist Association Quality Assurance
Program
i R Studio Team (2015). R Studio: Integrated Development for R.
R Studio, Inc., Boston, MA URL http://www.rstudio.com/
j MedCalc Software bvba, Mariakerke, Belgium; https://www.
medcalc.org; 2016
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